Ignite Your Senses,
Rediscover Smell
and Taste
The first pharmaceutical therapy
for smell and taste loss.
At Cyrano Therapeutics, we’re dedicated to developing therapies for people dealing with long-term loss of smell and taste. Prior to the COVID-19 pandemic, this condition affected over 15 million people in the U.S., with about 4 million cases resulting from flu viruses. Since COVID-19, however, the prevalence has increased over tenfold, with thousands of new cases emerging daily. This surge highlights the urgent need for effective treatments, and we’re committed to advancing solutions that restore these essential senses and enhance quality of life for those impacted.
Our Clinical Trial
This study is a 32-week, randomized, double-blinded, placebo-controlled trial evaluating the safety and effectiveness of CYR-064 as a potential treatment for hyposmia, the partial loss of smell. Beginning with a 4-week screening period to confirm participant eligibility, the trial aims to contribute valuable insights into the treatment of smell disorders by rigorously testing CYR-064’s impact on restoring olfactory function.
Learn more about olfactory dysfunction
Olfactory dysfunction, or the loss or impairment of the sense of smell, affects millions worldwide. This condition, often caused by viral infections, head trauma, or neurodegenerative diseases, impacts more than just the ability to detect scents; it can significantly affect quality of life, safety, and mental health. People with olfactory dysfunction may struggle with food enjoyment, recognizing hazards like gas leaks or smoke, and even social interactions. Research and treatment advancements, such as those by Cyrano Therapeutics, aim to restore this essential sensory function.
Olfactory System Explained
